COVID-19 has emerged as a global pandemic. It mainly manifests as pneumonia, which may deteriorate into severe respiratory failure. The major hallmark of the disease is the systemic inflammatory immune response characterized by cytokine storm (CS). CS is marked by elevated levels of inflammatory cytokines, mainly interleukin-6 (IL-6), IL-8, IL-10, tumor necrosis factor-α (TNF-α) and interferon-γ (IFNγ). Of these, IL-6 is found to be significantly associated with higher mortality. IL-6 is also a robust marker for predicting disease prognosis and deterioration of the clinical profile. (1) IL-6 was detectable in the breath condensate of all healthy nonsmokers but was significantly higher in COPD patients. Exhaled breath condensate is totally noninvasive and highly acceptable to patients. The collection procedure has no effect on airway function or inflammation, and there is growing evidence that abnormalities in condensate composition may reflect biochemical changes in airway lining fluid. This method has been successfully used in previous studies to investigate several inflammatory markers in COPD and asthmatic patients. (2) Il-6 is produced in the lung by interstitial fibroblasts, alveolar macrophages, and large-vessel and bronchial epithelial cells.These studies and our novel method after clinical trials may open the field for future therapies for COVID-19 and post-COVID-19 lung fibrosis by inhaler transport medicines as a new challenge for overcoming sequelae of this pandemic. This suggested a new procedure for the measurement of exhaled IL-6. We studied which IL-6 is risky is IL-6 produced from airway or endocrine IL-6 or immune IL-6. We can classify IL-6 as cytokine storm under pathological conditions to three mains of sources as immune IL-6 produced from respiratory system like interstitial fibroblasts and bronchial epithelial cells and fibroblast, second endocrine IL-6 produced from zona glomerulosa of adrenal glands stimulated by ACTH and immune IL-6 from macrophages and other immune cells. From previous studies we need a procedure acceptable to patients and easy, noninvasive, sensitive so we plan for clinical trial registered at clinicaltrials.gov about measurement of interleukin-6 at exhaled condensate of covid-19 patients and post-19 covid patients with lung fibrosis as a novel study which may be a useful tool, easy, sensitive for early intervention with anti-il6 medications and determine the degree of severity by inflammatory markers for intensity of airway inflammation.